Brief: Qyuns Therapeutics Enters License & Collaboration Agreement With LE2025 Therapeutics AG
22/12/2025 01:08
Dec 22 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK: ENTERS LICENSE & COLLABORATION AGREEMENT WITH LE2025 THERAPEUTICS AG GROUP TO RECEIVE TOTAL OF UP TO $700 MILLION PAYMENTS, INCLUDING UPFRONT PAYMENT, OTHERS LE2025 GRANTED EXCLUSIVE RIGHTS FOR QX027N DEVELOPMENT GLOBALLY EXCEPT FROM MAINLAND CHINA, OTHERS Further company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qyuns Therapeutics
See all newsBrief: QYUNS Therapeutics Posts HY Adjusted Profit Of RMB202.5 MLN
Brief: Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis
Brief: Qyuns Therapeutics Says Saifu Juli To Buy 34% Of Cellularforce For RMB86.02 Million
Brief: Qyuns Therapeutics Repurchases 3.43 Million Shares As Treasury Shares From Nov 6, 2025 To June 9
Brief: Qyuns Therapeutics Co Receives Milestone Payment From Roche